Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC and JS001 in Urothelial Cancer
NCT04264936Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in urothelial carcinoma (UC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Adverse events at 1 year and Maximal Tolerated Dose at 1 year. Status: unknown.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04264936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264936.